Medtech investors have to be a particular breed, with an acceptance that returns are not likely to be in typical investment timescales and that multiple investment rounds will probably be required. When you throw in that a typical clinical trial can be £500k, which might actually disprove your theory they can be unattractive to the uneducated medtech investor.
The comment re resistance is so relevant. I deal with a number of NHS innovation directors who are constantly stifled by existing processes, such as procurement. Like for like comparisons don't always work when you are dealing with an innovation but often the "computer says no."
Medtech investors have to be a particular breed, with an acceptance that returns are not likely to be in typical investment timescales and that multiple investment rounds will probably be required. When you throw in that a typical clinical trial can be £500k, which might actually disprove your theory they can be unattractive to the uneducated medtech investor.
The comment re resistance is so relevant. I deal with a number of NHS innovation directors who are constantly stifled by existing processes, such as procurement. Like for like comparisons don't always work when you are dealing with an innovation but often the "computer says no."
I agree with the comments about Charco, Lucy and her team really do listen to us in the PD community, and take on board what we say.